Loading...
•
Sep 30, 2023
Innoviva Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements, and provided an overview of its key business initiatives.
Key Takeaways
Innoviva reported a net income of $82.0 million for Q3 2023, with gross royalty revenue from GSK at $57.0 million and net product sales and license revenue at $13.7 million. The company launched XACDURO® and announced positive topline Phase 3 zoliflodacin data.
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in Q3 2023.
Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023.
Repurchased $11.0 million of common stock.
Forward Guidance
No specific forward guidance was provided in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...